Understanding GLP-1 News: A Reviewer's Guide to the Headlines
A calm, physician-led way to read drug-trial headlines so you are neither misled by hype nor frightened by numbers.
Understanding GLP-1 news starts with one habit: read past the headline to the source. A topline company press release is early, promotional, and incomplete; a peer-reviewed publication is the checked version. Before you react to a big percentage, ask what trial it came from, whether the drug is FDA-approved yet, and whether the number is an average. That short pause protects you from both hype and fear.
What is the difference between a topline press release and a peer-reviewed study?
A topline press release is the first public signal that a trial hit its goal. It is written by the company that ran the study, it usually lands months before the full data, and it shares the flattering top-line result without the fine print. None of that makes it dishonest. It is simply an early headline, not the finished record.
The peer-reviewed publication is where independent experts pressure-test the work. It reports who was studied, how long, what dropped out, and what the confidence intervals were. When you see coverage of a trial, look for the phrase "published in" a journal. If the article only cites "topline results reported" by a company, you are reading the trailer, not the film. Both have their place. I just read them with different levels of certainty.
What do trial names like STEP, SURMOUNT, and SELECT mean?
Those capitalized names are program labels, not grades. Each one is a family of trials for a particular drug and question. Knowing the family helps you place a headline quickly.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trial- STEP studied semaglutide for weight. In STEP-1, average weight reduction was about 14.9 percent of body weight.
- SURMOUNT studied tirzepatide for weight. In SURMOUNT-1, the average was about 20.9 percent.
- SELECT asked a different question: in adults with established cardiovascular disease and overweight or obesity but not diabetes, semaglutide sold as Wegovy (Novo Nordisk) reduced major cardiovascular events by about 20 percent.
- FLOW looked at kidneys: in type 2 diabetes with chronic kidney disease, semaglutide reduced major kidney events by about 24 percent.
- ATTAIN and TRIUMPH are newer programs for investigational drugs that are not yet FDA-approved.
When a headline shouts a number, the trial name tells you which question was actually asked. Weight, heart, and kidney outcomes are not interchangeable.
Why does approval still take time after a Phase 3 success?
Drug testing moves through phases. Early phases check safety and dose in small groups. Phase 3 is the large, long, comparison-against-placebo stage that regulators weigh most heavily. When you read "phase 3 trial," you are looking at serious evidence.
Even so, a positive phase 3 result is not an approval. Two examples in the current news cycle are orforglipron, an investigational once-daily oral GLP-1 that showed about 12.4 percent average weight reduction at the highest dose in the ATTAIN-1 phase 3 trial, and retatrutide, an investigational triple agonist that showed about 28.3 percent average reduction at the 12 mg dose in TRIUMPH-1 topline results. Both are genuinely promising. Neither is FDA-approved yet. The agency still reviews the full submission, and that review is part of what keeps the finished product trustworthy.
Why do average results not tell me my result?
This is the point I repeat most often in the exam room. Every headline number is an average across a whole trial. Some participants lost far more than the average, some far less, and a few lost little. "Up to 22.5 percent" is a dose-qualified ceiling from one arm of a study, not a typical outcome.
Your own result depends on your biology, your dose tolerance, your other conditions, and the daily habits around the medication. That last part matters more than any headline. Without resistance training and enough protein, lean tissue can make up roughly a quarter to 40 percent of the weight someone loses, which is why we pair therapy with strength work and protein targets commonly cited around 1.2 to 2 grams per kilogram of body weight per day. A number in the news is a starting expectation to discuss, not a promise about you.
How do percentages get dramatized in headlines?
Percentages are easy to stretch. A relative reduction of "20 percent fewer events" sounds enormous, and it can be meaningful, but it describes a change relative to the placebo group, not one in five people avoiding an event. Weight-loss figures get the opposite treatment: a best-case dose gets promoted to a general expectation. Neither framing is a lie. Both leave out context.
The fix is boring and reliable. Ask three questions. Percent of what? Compared to whom? Over how long? FLOW, for instance, reported a hazard ratio of 0.76 for kidney events, about an 18 percent reduction in cardiovascular events, and about a 20 percent reduction in death from any cause, over years, in a specific high-risk group. Those details are where the real meaning lives.
Why is a newer drug not automatically better for me?
Newer is not the same as better-for-you. The right medication is the one that fits your health history, your tolerance, your goals, and your budget. An older, well-studied option with years of safety data can be the wiser choice for one person, while a newer approval fits another. Recent approvals show how targeted this has become: semaglutide sold as Wegovy (Novo Nordisk) gained an FDA indication for MASH with moderate to advanced liver fibrosis in August 2025 after the ESSENCE trial, and tirzepatide sold as Zepbound (Eli Lilly) was approved for moderate-to-severe obstructive sleep apnea in December 2024. Those are specific matches to specific conditions, not a ranking of which drug is best overall.
One more honest note that headlines rarely lead with: obesity is a long-term condition. In extension data, stopping treatment led to substantial weight regain, and in the STEP-1 extension roughly two-thirds of lost weight returned within a year. The plan matters more than the molecule.
How should I bring a headline to my clinician?
Bring the actual article, not just the memory of it. A screenshot or link lets us find the trial, the phase, and whether it was a press release or a published paper. Then we can ask the useful questions together: does this apply to someone with my history, is this drug approved for this use, and does anything here change my plan.
At New Hope Weight Loss and Wellness, our telehealth visits are built for exactly that kind of conversation. A consult is $119, and options include compounded semaglutide at $166 a month, about $5.50 a day, and compounded tirzepatide at $233 a month, about $7.70 a day. Compounded semaglutide and tirzepatide are not FDA-approved and are not identical to the brand versions, and results vary by individual. A headline is a fine reason to start a conversation. It should not be the one making your decision.
Trademark note: Ozempic and Wegovy are trademarks of Novo Nordisk. Mounjaro and Zepbound are trademarks of Eli Lilly. New Hope Weight Loss and Wellness is not affiliated with either company.
Frequently asked questions
How can I tell if a GLP-1 headline is based on a press release or a real study?
Look at how the result is sourced. If the coverage says results were 'reported' or 'topline' by a company, it is likely an early press release with limited detail. If it says the trial was 'published in' a medical journal, it has been peer-reviewed, which means independent experts checked the methods and full data. Both can be accurate, but the published version carries more certainty.
What do GLP-1 trial names like STEP, SURMOUNT, and SELECT actually mean?
They are program names for groups of trials, each tied to a drug and a question. STEP studied semaglutide for weight, SURMOUNT studied tirzepatide for weight, SELECT looked at cardiovascular events, and FLOW looked at kidney outcomes. ATTAIN and TRIUMPH are newer programs for investigational drugs that are not yet FDA-approved. The name tells you which question the trial was designed to answer.
If a Phase 3 trial succeeds, why is the drug not available right away?
A successful phase 3 trial is strong evidence, but it is not approval. The FDA still reviews the full data submission before a drug can be marketed for a use. For example, orforglipron and retatrutide have shown promising phase 3 results but are not yet FDA-approved. That review step is part of what keeps approved products trustworthy.
Does a headline weight-loss percentage predict how much I will lose?
No. Headline figures are averages across an entire trial. Some participants lost much more and some much less, and dose-qualified numbers like 'up to 22.5 percent' are ceilings, not typical results. Your outcome depends on your biology, tolerance, and daily habits, including strength training and protein intake. Treat a headline number as a starting point for discussion, not a promise.
Is a newer GLP-1 drug better than an older one?
Not automatically. The best medication is the one that fits your health history, tolerance, goals, and budget. An older, well-studied option can be the right choice for one person while a newer approval suits another. Recent approvals, such as semaglutide for fatty liver disease and tirzepatide for sleep apnea, are matches to specific conditions rather than an overall ranking.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.